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Viruses, enteric bacteria and parasites can all produce similar syndromes of acute enteritis, although the patho- 
physiology and molecular pathogenesis may vary widely. The severity of acute enteritis varies greatly, and only a small 
fraction of cases undergo medical evaluation, There are over 200 000 000 episodes of acute enteritis annually in the 
USA, of which approximately 7.5 000 000 are foodborne. Fewer than 20% of estimated cases have a known etiology. 
Nearly half of the more than 4 000 000 cases of known foodborne bacterial enteritis are attributed to Curnpylobacter 
infections. The FoodNet active population-based surveillance system has demonstrated geographic variation in the 
incidence of Cumpylobacter infection, and generally declining incidence since 1996. Cumpylobacter jejuni infections 
vary in severity and duration. Antimicrobial therapy, especially if administered early, may hasten clinical resolution 
by 2-3 days. Therapy is generally restricted to individuals with moderate-to-severe disease and high-risk individuals 
(underlying immunodeficiency, chronic illness,,extremes of age, etc.). Approximately 10-15% of C. jejuni isolates are 
fluoroquinolone resistant, although most strains are macrolide susceptible. Several acute intra-abdominal as well as 
extraintestinal complications can occur following C. jejuni enteritis, although bacteremia and metastatic infection 
are rare, except in high-risk patients. Post-infectious syndromes include post-dysenteric bowel dysfunction, the less 
frequent but more severe reactive arthritis (l%), and Guillain-Barre syndrome (0.1%). The recent demonstration 
that antibiotic administration for Escherichia coli 0157:H7 hemorrhagic enteritis increases the risk of hemolytic- 
uremic syndrome 5-lo-fold forces reconsideration of empirical broad-spectrum antibiotic therapy for acute hemor- 
rhagic enteritis, and supports narrow-spectrum erythromycin therapy for acute enteritis. 
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INTRODUCTION 
Intestinal infection by a wide variety of pathogens 
results in the common syndrome of acute enteritis. 
Enteric pathogens associated with the gastroenteritis 
syndrome encompass a wide variety of viruses, enteric 
bacteria, and enteric parasites. The pathophysiology 
and molecular pathogenesis of enteritis caused by these 
etiologic agents vary widely. Among bacterial pathogens, 
there can be one or more pathogenic mechanisms, 
including luminal infection and toxin production, local 
(epithelial) adherence, and/or local invasion with vari- 
able rates of systemic dissemination. The epidemiologic 
features of gastroenteritis caused by different pathogens 
vary widely, with differing percentages of illness due to 
foodborne infection, direct fecal contamination, direct 
person-to-person contact, waterborne exposure, animal 
exposure, travel, etc. Thus, the most important etiologic 
agents of acute enteritis vary widely among different 
locations throughout the world. 
Address correspondence to Mark S. Pasternack, Infectious Disease 
Unit, Massachusetts General Hospital, 149 13th Street, Charlestown, 
MA 02129, USA 
E-mail: mpasternack@partners.org 
Conflict of interest: The author has served as a consultant to Bayer 
Corporation. 
In the USA, most episodes of gastroenteritis are 
attributable to viral infection, and produce only mild-to- 
moderate morbidity. Only a small fraction of episodes is 
evaluated by a physician, and only a subset of these ill 
individuals undergoes laboratory investigation. Routine 
diagnostic methodology is restricted to the detection of 
bacterial and parasitic diseases and only limited causes 
of viral gastroenteritis (e.g. rotavirus). In 1996, FoodNet 
(Foodborne Disease Active Surveillance Network) was 
established; this large-scale CDC-sponsored program 
monitors the incidence of foodborne enterobacterial 
disease in seven selected geographic areas which contain 
roughly 7.5% of the US population. In addition, FoodNet 
performs population and physician surveys to determine 
the frequency of physician visits for acute enteritis and 
the frequency of laboratory investigations to facilitate 
national incidence estimates.’ It is estimated that only 
2.5-3% of non-dysenteric bacterial enteritides, and only 
5% of episodes of bloody diarrhea, are captured by cur- 
rent active or passive surveillance systems in the USA.2 
EPIDEMIOLOGY OF FOODBORNE ENTERITIS 
Despite the uncertainties introduced by such extrapola- 
tions, it is no surprise that gastrointestinal infections are 
exceedingly common. For the USA, 211 million episodes 
of acute gastroenteritis were estimated to have occurred 
in 1997, based on FoodNet data as reported by Mead 
et al.* A global weighted estimate of foodborne trans- 
mission (36%) was created by pooling estimates of 
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foodborne transmission and incidence among known 
enteropathogens, yielding an estimated 76 million food- 
borne enteritis episodes annually. Among the nearly 
39 million enteritis cases of known etiology, bacterial 
enteritis was responsible for 5.2 million cases (- 14%); 
among these episodes of known etiology, 13.8 million 
(36%) were foodborne, and 4.2 million were due to 
bacterial pathogens. Almost half of the total episodes 
of bacterial enteritis (2.45 million, 47%) and foodborne 
bacterial episodes (1.96 million) were attributed to 
Campylobacter infections, making Campylobacter the 
most common cause of bacterial enteritis. Campylo- 
batter jejuni accounted for nearly all of the speciated 
Campylobacter isolates. It is important to note that 
routine antibiotic-containing selective media and in- 
cubation at 42°C are optimized to recover C. jejuni, and 
recovery of less thermophilic Campylobacter species is 
probably quite inefficient. Salmonella, Shigella, patho- 
genic Escherichia coli, Yersinia and E. coli 0157:H7 
accounted for most of the remaining episodes. The rates 
of severe illness as reflected by hospitalization differed 
among enteropathogens, so that Salmonella infections 
among hospitalized patients (16 430) exceeded those 
attributable to Campylobacter (13 174). 
It is surprising, perhaps, that only 18% of the total 
gastroenteritis episodes (38.6 million) could be attri- 
buted to known pathogens. It is likely that many repre- 
sented infections by known pathogens that were not 
recovered through laboratory evaluation, and that many 
others reflect presently unknown pathogens. Enteroviral 
infections may have been responsible for a portion of 
the unclassified cases, but were not tabulated separately. 
Additional important epidemiologic aspects of 
bacterial enteritis have been provided by FoodNet. 
In 1999, Campylobacter was documented in 37% and 
Salmonella in 42% of bacterial enteritis episodes, but 
Campylobacter is considered the most common bacterial 
infection, due to different rates of investigation of symp- 
tomatic illnesses. The incidence of all causes of bacterial 
enteritis peaked during the summer months, and 
there was considerable variation in regional incidence 
observed among the different enteropathogens. There 
was a generally declining trend in the incidence of 
Campylobacter infections (23.5-17.5/100 000, a 25% 
decline) during 1996-99. The 2000 incidence increased 
to 20.1/100 000 among the original five sampling sites, 
although the incidence among all FoodNet sites was 
15.7/100 OO0.3 Each enteropathogen possesses distinct 
epidemiologic features. For example, large outbreaks of 
Campylobacter enteritis are rare, and virtually all cases 
occur sporadically, even though the minimal infective 
inoculum for C. jejuni is approximately 1000 colony- 
forming units (CFUs). This inoculum is far smaller than 
that of the salmonellae, yet it is the latter which are 
commonly associated with outbreaks. There is very 
limited person-to-person spread of Campylobacter in- 
fection, and outbreaks of daycare center Campylobacter 
infections have not been reported in the USA. 
PATHOGENESIS 
C. jejuni produces local invasion of the small and large 
intestine and evokes a local acute inflammatory response. 
However, C. jejuni strains are generally susceptible to 
lysis by human serum,4 and, as a result, bacteremia and 
metastatic infections are quite rare in otherwise normal 
hosts. Bacteremia occurs in fewer than 1% of otherwise 
healthy patients with C. jejuni enteritis (although the 
blood culture rate in patients with acute enteritis is 
believed to be 10w).~-~ Campylobacter enteritis evokes 
a local and systemic antibody response. The humoral 
immune response is believed to be protective in indi- 
viduals who are repetitively infected, such as individuals 
residing in underdeveloped regions with high endemic 
rates of Campylobacter infection. Both cellular and 
humoral immunity appear to be important host defense 
mechanisms, since patients with hypogammaglobu- 
linemia*v’ and HIV-infected individuals with advanced 
immunodeficiency lo-l3 are at risk of developing severe 
refractory or chronic relapsing Campylobacter enteritis. 
Epidemiologic data obtained early in the AIDS era 
suggested that HIV-infected men had a 40-fold 
increased risk for Campylobacter infection, and a far 
greater rate of bacteremia (16%) in the setting of acute 
enteritisi but more recent data cast doubt on these 
early findings. l2 Case reports of severe enteritis refractory 
to medical therapy, and even acute septic shock com- 
plicating Campylobacter enteritis in HIV-infected 
individuals, have been published,i5 but the poor out- 
come seemed to correlate with advanced disease 
reflected by CD4+ lymphocyte depletion and marked 
immunosuppression, rather than with HIV infection per 
se.” In such individuals, long-term antibiotic admini- 
stration to control chronic symptoms was commonly 
associated with the appearance of antibiotic-resistant 
C. jejuni. Sequential courses of antibiotic therapy led to 
multiresistant strains and poor clinical outcomes. The 
use of macrolides or rifabutin as prophylaxis against 
Mycobacterium avium-intracellulare infections in indi- 
viduals with advanced HIV disease may also offer pro- 
tection against Campylobacter infectioni and reduce 
the severity or chronicity of enteritis in these patients. 
Hypogammaglobulinemic patients with refractory 
Campylobacter infection have benefited from immuno- 
globulin replacement therapy in addition to anti- 
biotics.17,‘8 
CLINICAL FEATURES 
The features of C. jejuni enteritis are largely indistin- 
guishable from those of other forms of acute bacterial 
enteritis.7J9g20 After an incubation period of several days 
(usually 2-5 days, but may range from 1 to >7 days, 
perhaps inversely related to inoculum size), a brief 
prodrome with influenza-like symptoms of fever, 
myalgias and headache may appear, followed by pro- 
minent symptoms of gastroenteritis. Fever, cramping 
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abdominal pain and diarrhea supervene. The severity of 
diarrhea ranges from mild to severe (8-15 stools on the 
worst day), and may be accompanied by dysenteric 
symptoms of bloody diarrhea in nearly half of patients, 
and tenesmus in roughly one-quarter. Emesis is also 
seen in one-quarter of patients. Stool examination 
confirms fecal blood in the majority of patients, and 
demonstrates the presence of fecal leukocytes in over 
75% of cases. Symptoms usually wane in less than a 
week, although symptoms may persist (usually for less 
than 2 weeks) in a fraction of patients. Fecal shedding 
of C. jejuni may persist for several weeks, despite 
uncomplicated clinical recovery. Although most infected 
individuals demonstrate classic manifestations of bac- 
terial enteritis, asymptomatic infections have been 
documented in as many as 25% of individuals investi- 
gated during an outbreak. 7 In occasional individuals, 
systemic complaints and abdominal pain are not accom- 
panied by diarrhea, and patients may undergo laparo- 
tomy for possible appendicitis. 
ACUTE COMPLICATIONS 
Although the vast majority of C. jejuni enteritis episodes 
resolve with supportive care, complications are occas- 
ionally seen. These have been classified by Allos and 
Blaser as intra-abdominal (gastrointestinal hemorrhage, 
mesenteric lymphadenitis, appendicitis, cholecystitis, 
toxic megacolon, pseudomembranous colitis, pancreatitis, 
peritonitis, intestinal obstruction) and extraintestinal. 
The extraintestinal complications represent metastatic 
infections following C. jejuni bacteremia. There have 
been case reports describing a variety of parenchymal 
infections, including meningitis, septic arthritis, septic 
abortion, endocarditis, bursitis, and cellulitis. In many of 
these instances, the patient was immunocompromised or 
was chronically ill. In contrast to the predominantly 
local sequelae of C. jejuni infections, C. fetus resists the 
bactericidal activity of serum, and is associated with 
a higher rate of bacteremia complicating enteritis, and 
a higher rate of metastatic infections,*’ especially in 
conjunction with underlying immunodeficiency. 
LATE COMPLICATIONS 
Persistent symptoms of abdominal discomfort and 
alterations in bowel pattern, including passage of mucus, 
bloating, urgency, and episodic diarrhea1 movements 
lasting 3 to >12 months, have been reported in up 
to 25% of patients with confirmed bacterial enteritis. 
This has been termed post-dysenteric irritable bowel 
syndrome, and has been studied in patients recovering 
from Cumpylobacter enteritis.22 Presumably, this is a 
sequela of more severe acute disease, since mildly ill 
individuals are unlikely to seek medical care or undergo 
stool culture. Rectal biopsies in patients with continued 
gastrointestinal complaints demonstrated a variety of 
histopathologic abnormalities, including increased 
enteroendocrine cells, increased intraepithelial and 
lamina propria CD3’ lymphocytes, and reduced macro- 
phages; in addition, abnormal gut permeability was pre- 
sent. Symptoms wane in most patients, but on occasion 
can persist for extended intervals. 
Noninfectious reactive arthritis is observed in 
approximately 1% of individuals recovering from 
Curnpylobacter enteritis; a similar syndrome of reactive 
arthritis follows enteritis caused by a variety of bacterial 
enteropathogens. 23 Asymmetric oligoarticular or mono- 
articular arthritis, predominantly involving the lower 
extremities or the small joints of the hands, develops 
within l-6 weeks following an episode of acute 
enteritis.24 The risk of this complication is increased 
among individuals bearing the HLA-B27 allele; up to 
60% of individuals with post-dysentery reactive arthritis 
are HLA-B27 positive. The course of symptomatic 
arthritis is highly variable, and may be self-limited over 
a course of weeks to months, recurrent, or occasionally 
persistent, with a waxing and waning course.The severity 
of acute C. jejuni enteritis does not appear to predict 
the severity of reactive arthritis, and antibiotic therapy 
has not been shown to reduce the risk or severity of 
this complication. The long-term prognosis is favorable, 
despite the short-term disability. 
Approximately 0.05-0.1% of patients recovering 
from Cumpylobucter enteritis are at risk of develop- 
ing Guillain-Barre syndrome, an acute autoimmune 
polyradiculoneuropathy which presents with areflexic 
flaccid paralysis and variable sensory abnormalities.25-27 
Different subtypes of the syndrome are associated 
with neuronal demyelination or axonal degeneration. 
Cumpylobucter infection is now recognized to be the 
most common precipitant of Guillain-Barre syndrome, 
accounting for roughly 2540% of cases, and seems to be 
preferentially associated with the more severe axonal 
degenerative process. Ascending motor weakness is 
generally rapidly progressive, and is often severe, 
mandating assisted ventilation, although ultimately 
favorable recoveries are observed in 85% of patients. 
Selected serotypes of C. jejuni (e.g. 0:19) appear to 
be particularly associated with the risk of subsequent 
Guillain-Barre syndrome. 25,27 Specific glycolipid moieties 
on the Cumpylobucter lipopolysaccharide closely re- 
semble normal human gangliosides, and it is postulated 
that enteric infection triggers the production of cross- 
reactive antibodies which then attack neural structures.28 
MANAGEMENT 
The foundation of management of acute enteritis is 
supportive care. 7,20 Oral rehydration, using clear liquids 
for mild symptoms and oral rehydration solution for 
moderate-to-severe symptoms, if necessary, is usually 
successful in preventing or reversing evolving de- 
hydration. Anti-motility agents are generally contra- 
indicated if moderate or severe symptoms are present. 
The role of antibiotic therapy in the treatment of acute 
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enteritis remains controversial, since most patients with 
mild disease improve uneventfully. Consideration of 
antibiotic therapy in the empirical management of 
bacterial enteritis is complicated by the contrasting 
outcomes of such therapy, depending on the entero- 
pathogen. The course of shigellosis is shortened by 
antibiotic therapy; the course of Cumpylobacter infection 
is probably shortened as we11,29,3o but controversy exists 
in this area.7 However, antibiotic therapy is not believed 
to improve the course of SaZmonelZa gastroenteritis. 
Rather, antibiotic therapy has been associated with 
prolonged stool carriage of Salmonella, and an increased 
risk of relapsing infection. In the case of Shiga toxin- 
producing E. coli, antibiotic therapy is believed to 
increase the risk of subsequent hemolytic-uremic 
syndrome.31 Empirical broad-spectrum antibiotic therapy 
for acute diarrhea became popular in the management 
of travelers’ diarrhea, where most infections are non- 
dysenteric in nature, and the majority of episodes are 
attributed to enterotoxigenic E. coEi.32 Recent recom- 
mendations mention azithromycin for empirical therapy 
of travelers’ diarrhea in areas where there may be an 
increased risk of fluoroquinolone-resistant Campylo- 
batter infection.33 However, empirical therapy for 
sporadic community-acquired enteritis, intended to treat 
a distinct panel of potential enteropathogens with 
differing likelihoods of response and definite potential 
therapy-associated risks, is more problematic. Empirical 
antibiotic therapy is considered for patients with 
moderate or severe disease, reflected by persistence of 
symptoms, presence of dysenteric symptoms and bloody 
diarrhea, and systemic features of severe il1ness.A lower 
threshold for therapy is appropriate for compromised 
individuals, particularly immunocompromised patients, 
debilitated and chronically ill individuals, and those at 
the extremes of age. 
TO TREAT OR NOT TO TREAT? 
Two strategies for antibiotic use may be considered: (1) 
early empirical antibiotic therapy administered at the 
time of initial presentation; or (2) specific therapy 
prescribed only after the recovery and identification 
(and susceptibility testing) of bacterial enteropathogens. 
Unfortunately, the time required for an etiologic 
diagnosis of acute enteritis is relatively long when 
compared to the natural history of most episodes. In the 
setting of mild or moderate illness, only a very small 
fraction of patients even undergo laboratory investi- 
gation. Such evaluation leads to specific antimicrobial 
therapy in an even smaller subset of patients, since many 
individuals have improved before etiologic information 
is available. Moreover, antibiotic susceptibility testing of 
isolated enteropathogens adds to this delay, and may not 
be routinely available, particularly for C. jejuni. Several 
clinical studies have suggested that empirical fluoro- 
quinolone therapy administered to patients with sporadic 
enteritis shortens the duration of acute diarrhea by 2- 
3 days for all bacterial enteropathogens, including 
Campylobacter. 3o However, some authors suggest that 
antibiotic therapy administered after 3 days of symp- 
toms is not likely to alter the clinical course of resolution 
significantly.7 The presence of severe or prolonged 
symptoms or bloody diarrhea might suggest the need for 
early therapy even in normal hosts (see caveats below). 
It is reasonable to consider empirical erythromycin 
therapy directed against C. jejuni in the setting of 
moderate-to-severe or refractory non-hemorrhagic 
enteritis. This probably represents less than half of the 
patients who seek medical attention for acute enteritis, 
i.e. 11% of patients with C. jejuni infection based on 
FoodNet extrapolations.2 The logic behind such narrow- 
spectrum therapy is discussed below. Antibiotic therapy 
should be considered strongly in pregnant mothers 
(avoiding fluoroquinolones), and in debilitated and 
immunocompromised individuals (particularly those with 
hypogammaglobulinemia or HIV infection). In these 
high-risk individuals, initial combination therapy with a 
macrolide as well as a fluoroquinolone might be con- 
sidered, with continued therapy guided by formal drug 
susceptibility testing. In immunocompromised individuals 
with bacteremia or metastatic infection, imipenem and/ 
or aminoglycoside therapy may be considered in cases 
of macrolide or fluoroquinolone resistance or initial 
failure. 
BROAD-SPECTRUM OR NARROW-SPECTRUM 
THERAPY? 
Decisions to administer early empirical antibiotic 
therapy are confounded by the evolving resistance 
patterns of the commonly encountered bacterial entero- 
pathogens. Over the past 15 years, fluoroquinolones 
have been popular for the empirical therapy of acute 
bacterial enteritis because of their broad efficacy against 
Salmonella, Shigella, Campylobacter and E. coli isolates. 
However, the demonstration that many enteropathogens, 
whether acquired domestically or imported, may possess 
fluoroquinolone resistance has complicated the situation. 
In the USA, lo-15% of domestically acquired C. jejuni 
isolates are fluoroquinolone resistant.“4 Imported 
isolates often have far greater rates of resistance,33-35 
and thus careful epidemiologic information regarding 
recent travel exposure or fluoroquinolone use should be 
explored before therapy is selected. Nevertheless, in the 
absence of risk factors associated with an increased 
resistance rate, fluoroquinolone therapy remains highly 
active against most enteropathogens in this country. In 
contrast to the trend toward increased fluoroquinolone 
resistance, the efficacy of macrolide therapy for C. jejuni 
infections has remained robust. Erythromycin, for 
example, remains an effective narrow-spectrum therapy 
against C. jejuni infections in severely ill or immuno- 
compromised individuals, with erythromycin resistance 
rates generally below 5% in the USA. Historically, the 
narrow spectrum of action against C. jejuni and the 
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higher rate of gastrointestinal side effects associated 
with erythromycin have restricted its use in the em- 
pirical treatment of acute enteritis as well as for the 
specific therapy of mild or moderate C. jejuni enteritis. 
As will be discussed below, the very selectivity of 
erythromycin for C. jejuni infections may be considered 
an advantage rather than a limitation. Nevertheless, the 
availability of newer, broad-spectrum macrolides such as 
azithromycin, which are better tolerated and possess 
significant activity against a broad range of entero- 
pathogens, has provided an alternative choice for initial 
broad-spectrum empirical therapy and for therapy of 
proven C. jejuni infections in erythromycin-intolerant 
individuals. 
PRIMUM NON NOCERE: THE MANAGEMENT 
OF HEMORRHAGIC DYSENTERY 
An additional dilemma confronts the clinician con- 
sidering empirical antibiotic therapy for severe cases of 
enteritis which present as hemorrhagic dysentery. Both 
Campylobacter and enterohemorrhagic E. coli (0157:H7 
as well as Shiga toxin-expressing non-0157 strains) 
may lead to hemorrhagic colitis, and cannot be readily 
distinguished on clinical grounds. Although early anti- 
biotic therapy may hasten recovery from C. jejuni 
enteritis, antibiotic therapy is not thought to alter the 
course of hemorrhagic E. coli infections. E. coli 0157:H7 
infections in children are associated with a lO-15% risk 
of developing the hemolytic-uremic syndrome, in which 
hemolytic anemia, thrombocytopenia and renal failure 
develop shortly after the onset of diarrhea, and this risk 
is enhanced (5-lo-fold) when antibiotic therapy is 
administerede3’ The hemolytic-uremic syndrome is an 
important cause of acute renal failure, leading to death 
in 3-5% of patients and chronic renal failure among 
some survivors. The syndrome of thrombotic thrombo- 
cytopenic purpura, which resembles hemolytic-uremic 
syndrome but has more prominent neurologic findings, 
can occur in adult patients following E. coli 0157:H7 
infection. 
These post-infectious syndromes are thought to 
occur following the systemic release of Shiga-like toxin 
expressed by an integrated bacteriophage during the 
course of hemorrhagic enteritis. The risk of developing 
these complications seems to correlate with the severity 
of the initial hemorrhagic enteritis. Paradoxically, anti- 
biotic therapy appears to promote bacteriophage 
production and expression of the bacteriophage toxin. 
Trimethoprim, fluoroquinolones and possibly even 
broad-spectrum macrolide agents such as azithromycin 
are potential inducers of Shiga toxin production. Thus, 
individuals with more severe disease (e.g. with leuko- 
cytosis and earlier stool recovery of E. coli 0157:H7), 
especially children and older adults, are at greatest risk 
for the development of hemolytic-uremic syndrome or 
thrombotic thrombocytopenic purpura. However, these 
are the same patients whose severe hemorrhagic colitis 
might prompt early empirical therapy, in the hope of 
ameliorating symptoms. These considerations are not 
merely theoretical concerns; the number of fatalities 
attributable to Shiga-toxin-expressing E. coEi is com- 
parable to that for Campylobacter.2 Current recom- 
mendations urge caution when considering empirical 
antibiotic therapy for acute enteritis.36 Shiga-like toxin 
is also associated with enterohemorrhagic E. co/i 
infections in non-0157:H7 strains, and can produce 
hemolytic-uremic syndrome and thrombotic thrombo- 
cytopenic purpura. 37 This creates additional diagnostic 
uncertainty, since routine screening for these strains 
is not undertaken. Thus, antibiotic therapy for the 
treatment of most hemorrhagic enteritis syndromes 
should be restricted to erythromycin to treat putative 
C. jejuni infection, or should be delayed until the positive 
isolation of C. jejuni, Shigella, or less commonly observed 
enteropathogens. This approach would specifically 
spare individuals with salmonellosis or E. coli 0157:H7 
infection, and perhaps all patients with hemorrhagic 
colitis whose stool cultures fail to yield identifiable 
enteropathogens, from broad-spectrum agents which 
might trigger hemolytic-uremic syndrome. 
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the infection. I would submit that this might be, apart 
from anything else, a reasonable human reservoir. It 
might persist for long enough to jump from person to 
person, and it is probably still worth looking at. 
M. Pasternack: As was mentioned earlier, I can say that 
Campylobacter outbreaks are not common. The data on 
person-to-person spread have been hard to support. 
Usually, daycare centers answer that question for us, and 
there haven’t been many daycare center cases. That 
there is a huge pyramid out there goes without saying. 
There are some remarkable FoodNet observations that 
I didn’t mention, It is estimated that only 5% of patients 
with hemorrhagic enteritis ever seek medical care. Nine- 
teen of 20 cases of bloody diarrhea at home are not 
reported to a physician. Of patients with suspected 
Campylobacter jejuni disease, only one in 38 sees a 
physician. We know there is a huge amount of disease 
that we are not detecting. 
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and Campylobacter, so that one ends up being cultured 
but is not necessarily the etiologic agent? 
M. Pasternack: I think that there are situations where 
that has occurred. It is almost always in an outbreak 
situation, where dually contaminated food products have 
been available at a large gathering, and in returning 
travelers who were dually infected, having eaten food in 
another country. In terms of sporadic disease, I would say 
that it is quite rare to recover two bona fide entero- 
pathogens from a single clinical illness. In a large series, 
usually a few per cent will turn out to be dually infected. 
Cases usually come from food outbreaks. 
C. Hofacre: How often would anyone look? 
M. Pasternack: Routine stool cultures should identify 
the vast majority of dual infections through the use of 
conventional selective media. Sporadic dually infected 
individuals would not be subjected to stool testing in 
most instances, since only a few per cent of individuals 
with enteritis seek medical evaluation and stool testing. 
In epidemic situations, dual infections can be identified 
more readily and investigated by the CDC. 
E. Gonder: A number of times, you referred to waiting 
for a susceptibility test for Campylobacter, and my 
question is, how much do you rely on the laboratory 
report? I think that, probably, most clinical laboratories 
in the USA couldn’t do the right test unless they were 
using the E test. I always had the impression that even 
the E test might underestimate resistance. Unless a 
laboratory was using the E test, I wouldn’t have much 
confidence in their results. 
M. Pasternack: This is a good point; I suppose that I am 
lucky to work in a tertiary care hospital where I trust 
the bacteriology laboratory. Their analytical skills are of 
very high quality, and they are very prompt in providing 
us with information. You are absolutely right that, in 
many clinical situations, a patient provides a stool 
sample, and at the end of the day the sample is sent to a 
regional clinical laboratory, making the turn-around 
time too long for the analysis to be clinically useful. 
C. Thornsberry: I wouldn’t want to rely on a disk 
diffusion test. 
M. Pasternack: 1 accept that point. 
